EFFICACY AND SAFETY OF THE SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR, RELACORILANT (UP TO 400 MG/DAY), IN PATIENTS WITH ENDOGENOUS HYPERCORTISOLISM: RESULTS FROM AN OPEN-LABEL PHASE 2 STUDY
AACE ePoster Library. Pivonello R. 04/27/19; 262879; 648440
Rosario Pivonello
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Rate & Comment (0)
{{ help_message }}
{{filter}}